Skip To Main Content
Lilly
Menu closed
Lilly
    Lilly

    You are now leaving the LillyMedical website

    The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
    Click "Continue" to proceed or "Return" to return to LillyMedical.

    Diabetes Journal Publications

    This page includes links to Lilly sponsored trials and observational research that have been published in peer reviewed journals within the last 5 years. Each section is sorted by product and may be expanded for more information. The list of publications below is limited to products that have been approved for use and may contain information about doses, delivery devices, uses, formulations and populations different from product labeling. Clinical decisions should be based on the full safety and efficacy information contained in the product's Full Prescribing Information in the provided link below.

    If you have questions about a Lilly study not listed below or would like to request an electronic copy of one of the journal publications on this page, please call 1-800-LILLYRX (1-800-545-5979). For our publication linking statement click here.

    For all other requests, please visit our Contact Lilly services.

    Basaglar® (insulin glargine)

    Full Prescribing Information

    No Publication Journals

    No Publication Journals

    No Publication Journals

    Trajectory of glycated haemoglobin over time, using real-world data, in type 2 diabetes patients with obesity on a U-100 basal-bolus insulin regimen.
    Published Date: February 16, 2023
    Gaps Remain for Achieving HbA1c Targets for People with Type 1 or Type 2 Diabetes Using Insulin: Results from NHANES 2009─2020
    Published Date: April 17, 2023
    Predictors of insulin pump initiation among people with type 2 diabetes from a US claims database using machine learning.
    Published Date: May 11, 2023
    Real-World Patterns of Basal Insulin Use with Other Diabetes Medications Among People with Type 2 Diabetes Between 2014 and 2020.
    Published Date: May 15, 2023
    Barriers and Facilitators to the Initiation of Injectable Therapies for Type 2 Diabetes Mellitus: A Mixed Methods Study.
    Published Date: September 2, 2022
    Health care resource utilization and cost of severe hypoglycemia treatment in insulin-treated patients with diabetes in the United States
    Published Date: March 1, 2021
    Overcoming psychological insulin resistance: A practical guide for healthcare professionals.
    Published Date: March 27, 2021
    Trends in U.S. Insulin Use and Glucose Monitoring for People with Diabetes: 2009-2018.
    Published Date: July 5, 2021
    Evaluating the relationship between clinical and demographic characteristics of insulin-using people with diabetes and their health outcomes: a cluster analysis application.
    Published Date: July 8, 2021
    The Association Between Adherence to Insulin Therapy and Health Care Costs for Adults with Type 2 Diabetes: Evidence from a U.S. Retrospective Claims Database
    Published Date: September 21, 2020

    Glucagon™ (glucagon for injection [rDNA origin])

    Full Prescribing Information

    No Publication Journals

    No Publication Journals

    No Publication Journals

    Humalog

    Humalog® U-100 (insulin lispro injection) | Full Prescribing Information
    Humalog® U-200 (insulin lispro injection) | Full Prescribing Information
    Humalog® MIX50/50™ (50% insulin lispro protamine suspension 50% insulin lispro injection [rDNA origin]) | Full Prescribing Information
    Humalog® MIX75/25™ (75% insulin lispro protamine suspension 25% insulin lispro injection [rDNA origin]) | Full Prescribing Information

    No Publication Journals

    No Publication Journals

    No Publication Journals

    No Publication Journals

    Trajectory of glycated haemoglobin over time, using real-world data, in type 2 diabetes patients with obesity on a U-100 basal-bolus insulin regimen.
    Published Date: February 16, 2023
    Predictors of insulin pump initiation among people with type 2 diabetes from a US claims database using machine learning.
    Published Date: May 11, 2023
    The Burden and Impacts of Mealtime Insulin from the Perspective of People with Diabetes.
    Published Date: May 15, 2023
    Predicting Response to Bolus Insulin Therapy in Patients With Type 2 Diabetes.
    Published Date: May 20, 2022
    Barriers and Facilitators to the Initiation of Injectable Therapies for Type 2 Diabetes Mellitus: A Mixed Methods Study.
    Published Date: September 2, 2022
    Health care resource utilization and cost of severe hypoglycemia treatment in insulin-treated patients with diabetes in the United States
    Published Date: March 1, 2021
    Overcoming psychological insulin resistance: A practical guide for healthcare professionals.
    Published Date: March 27, 2021
    Trends in U.S. Insulin Use and Glucose Monitoring for People with Diabetes: 2009-2018.
    Published Date: July 5, 2021
    Evaluating the relationship between clinical and demographic characteristics of insulin-using people with diabetes and their health outcomes: a cluster analysis application.
    Published Date: July 8, 2021
    Missed and mistimed insulin doses in people with diabetes: a systematic literature review
    Published Date: July 16, 2021
    The Association Between Adherence to Insulin Therapy and Health Care Costs for Adults with Type 2 Diabetes: Evidence from a U.S. Retrospective Claims Database
    Published Date: September 21, 2020

    Humulin

    Humulin® R (U-100) (regular insulin human injection, USP [rDNA origin]) | Full Prescribing Information
    Humulin® R (U-500) (regular U-500 [concentrated] insulin human injection, USP [rDNA origin]) | Full Prescribing Information
    Humulin® 70/30 (70% human insulin isophane suspension and 30% human insulin injection [rDNA origin]) | Full Prescribing Information
    Humulin® N U-100 (human insulin [rDNA origin] isophane suspension) | Full Prescribing Information

    No Publication Journals

    No Publication Journals

    No Publication Journals

    No Publication Journals

    Lyumjev® (insulin lispro - aabc)

    Full Prescribing Information

    Ultra Rapid Lispro Lowers Postprandial Glucose and More Closely Matches Normal Physiological Glucose Response Compared to Other Rapid Insulin Analogs: A Phase 1 Randomized, Crossover Study
    Published Date: May 21, 2020
    Pharmacokinetics and Glucodynamics of Ultra Rapid Lispro (URLi) versus Humalog® (Lispro) in Patients with Type 2 Diabetes Mellitus: A Phase I Randomised, Crossover Study
    Published Date: May 29, 2020
    Pharmacokinetics and Glucodynamics of Ultra Rapid Lispro (URLi) versus Humalog® (Lispro) in Younger Adults and Elderly Patients with Type 1 Diabetes Mellitus: A Randomised Controlled Trial
    Published Date: May 29, 2020

    Ultra Rapid Lispro Demonstrates Similar Time in Target Range to Lispro With a Hybrid Closed-Loop System
    Published Date: November 25, 2021

    Improved postprandial glucose control with ultra rapid lispro versus lispro with continuous subcutaneous insulin infusion in type 1 diabetes: PRONTO-Pump-2
    Published Date: 09 March 2021
    Ultra Rapid Lispro Improves Postprandial Glucose Control and Time in Range in Type 1 Diabetes Compared to Lispro: PRONTO-T1D Continuous Glucose Monitoring Sub-Study
    Published Date: May 21, 2020
    Ultra Rapid Lispro Improves Postprandial Glucose Control Compared With Lispro in Patients With Type 1 Diabetes: Results from the 26-Week PRONTO-T1D Study
    Published Date: June 15, 2020
    Randomized Double-Blind Clinical Trial Comparing Ultra Rapid Lispro With Lispro in a Basal-Bolus Regimen in Patients With Type 2 Diabetes: PRONTO-T2D
    Published Date:** Online: 2 July 2020, Print: 20 November 2020
    Compatibility and Safety of Ultra Rapid Lispro with Continuous Subcutaneous Insulin Infusion in Patients with Type 1 Diabetes: PRONTO-Pump Study
    Published Date: December 31, 2020

    No Publication Journals

    Gaps Remain for Achieving HbA1c Targets for People with Type 1 or Type 2 Diabetes Using Insulin: Results from NHANES 2009─2020
    Published Date: April 17, 2023
    The Burden and Impacts of Mealtime Insulin from the Perspective of People with Diabetes.
    Published Date: May 15, 2023
    Trajectory of glycated haemoglobin over time, using real-world data, in type 2 diabetes patients with obesity on a U-100 basal-bolus insulin regimen.
    Published Date: February 16, 2023
    Predicting Response to Bolus Insulin Therapy in Patients With Type 2 Diabetes.
    Published Date: May 20, 2022
    Missed and mistimed insulin doses in people with diabetes: a systematic literature review
    Published Date: July 16, 2021
    Evaluating the relationship between clinical and demographic characteristics of insulin-using people with diabetes and their health outcomes: a cluster analysis application.
    Published Date: July 8, 2021
    Trends in U.S. Insulin Use and Glucose Monitoring for People with Diabetes: 2009-2018.
    Published Date: July 5, 2021
    Overcoming psychological insulin resistance: A practical guide for healthcare professionals.
    Published Date: March 27, 2021
    Health care resource utilization and cost of severe hypoglycemia treatment in insulin-treated patients with diabetes in the United States
    Published Date: March 1, 2021
    The Association Between Adherence to Insulin Therapy and Health Care Costs for Adults with Type 2 Diabetes: Evidence from a U.S. Retrospective Claims Database
    Published Date: September 21, 2020
    Predictors of insulin pump initiation among people with type 2 diabetes from a US claims database using machine learning.
    Published Date: May 11, 2023
    Barriers and Facilitators to the Initiation of Injectable Therapies for Type 2 Diabetes Mellitus: A Mixed Methods Study.
    Published Date: September 2, 2022

    Mounjaro® (tirzepatide)

    Full Prescribing Information

    Tirzepatide reduces appetite, energy intake, and fat mass in people with type 2 diabetes
    Published Date: March 01, 2023
    Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial
    Published Date: April 22, 2022
    Effects of Hepatic Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide
    Published Date: June 08, 2022
    Effects of Renal Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide
    Published Date: March 29, 2021
    A phase 1 multiple-ascending dose study of tirzepatide in Japanese participants with type 2 diabetes
    Published Date: October 13, 2021
    The novel dual glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 (GLP ‐1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long‐acting GLP ‐1 receptor agonists
    Published Date: June 10, 2020

    Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis
    Published Date: February 24, 2022
    The dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes: A post hoc analysis
    Published Date: September 20, 2021
    Effects of Tirzepatide, a Dual GIP and GLP-1 RA, on Lipid and Metabolite Profiles in Subjects with Type 2 Diabetes
    Published Date: October 05, 2021
    The dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes
    Published Date: August 16, 2020
    Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-Cell Function and Insulin Sensitivity in Type 2 Diabetes
    Published Date: November 24, 2020

    Time to weight plateau with tirzepatide treatment in the SURMOUNT-1 and SURMOUNT-4 clinical trials
    Published Date: January, 2025
    Tolerability and Weight Reduction of Tirzepatide in Adults with Obesity or Overweight with and without T2D in SURMOUNT-1 to -4 trials
    Published Date: January, 2025
    Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program
    Published Date: January, 2025
    Time to Reach Glycaemic and Body Weight Loss Thresholds with Tirzepatide in Patients with Type 2 Diabetes: A Pre-planned Exploratory Analysis of SURPASS-2 and SURPASS-3
    Published Date: March 31, 2023
    Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program
    Published Date: March 24, 2023
    Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis
    Published Date: February 24, 2022
    Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in patients with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial
    Published Date: April 22, 2022
    Efficacy of once-weekly tirzepatide versus once-daily insulin degludec on glycaemic control captured with continuous glucose monitoring in participants with type 2 diabetes (SURPASS-3 CGM): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial.
    Published Date: April 23, 2022
    Efficacy of tirzepatide 5, 10, and 15 mg versus semaglutide 2 mg in patients with type 2 diabetes: an adjusted indirect treatment comparison
    Published Date: May 19, 2022
    Safety and efficacy of once-weekly tirzepatide as add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes mellitus in Japan (SURPASS J-combo): a multi centre, randomised, open label, parallel group phase 3 trial
    Published Date: July 29, 2022
    Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial
    Published Date: July 29, 2022
    Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial
    Published Date: September 21, 2022
    Change of pharmacodynamics parameters following once-weekly tirzepatide treatment versus dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono sub-study).
    Published Date: October 02, 2022
    Achievement of glycemic targets with weight loss and without hypoglycemia in type 2 diabetes with once-weekly GIP and GLP-1 receptor agonist tirzepatide: a post-hoc analysis of the SURPASS-1 to -5 studies
    Published Date: December 13, 2022
    Safety and efficacy analyzes across age and body mass index subgroups in East Asian participants with type 2 diabetes in the phase 3 tirzepatide studies (SURPASS program)
    Published Date: December 22, 2022
    Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial.
    Published Date: February 8, 2021
    Tirzepatide versus Semaglutide Once Weekly for Patients with Type 2 Diabetes
    Published Date: June 24, 2021
    Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.
    Published Date: July 10, 2021
    Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
    Published Date: August 5, 2021
    Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial.
    Published Date: August 14, 2021
    Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.
    Published Date: November 13, 2021

    No Publication Journals

    Long-term cost-effectiveness analysis of tirzepatide versus semaglutide 1.0 mg for the management of type 2 diabetes in the United States.
    Published Date: January 18, 2023
    Physician Perceptions of Dose Escalation for Type 2 Diabetes Medications in the United States.
    Published Date: November 18, 2023
    Impact of Weight Change on Glycemic Control and Metabolic Parameters in T2D: A Retrospective US Study Based on Real-World Data
    Published Date: December 1, 2023
    An Economic Evaluation of the Relationship Between Glycemic Control and Total Healthcare Costs for Adults with Type 2 Diabetes: Retrospective Cohort Study.
    Published Date: December 1, 2023
    Exit Interviews Examining the Patient Experience in Clinical Trials of Tirzepatide for Treatment of Type 2 Diabetes.
    Published Date: May 6, 2022
    Patient Perceptions of and Preferences Between Characteristics of Injectable Diabetes Treatments.
    Published Date: July 23, 2021
    Obesity and glycemic control among people with type 2 diabetes in the United States: A retrospective cohort study using insurance claims data.
    Published Date: September 1, 2021

    Trulicity® (dulaglutide)

    Full Prescribing Information

    No Publication Journals

    No Publication Journals

    No Publication Journals

    An Economic Evaluation of the Relationship Between Glycemic Control and Total Healthcare Costs for Adults with Type 2 Diabetes: Retrospective Cohort Study.
    Published Date: December 1, 2023
    Greater Adherence and Persistence with Injectable Dulaglutide Compared with Injectable Semaglutide at 1-Year Follow-up: Data from US Clinical Practice.
    Published Date: March 6, 2022
    Association of Dulaglutide Initiation Timing With Treatment Patterns and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus in the United States.
    Published Date: May 24, 2022
    Are We There Yet? Increasing Use of Cardioprotective Antihyperglycemic Agents in Patients with T2DM and CVD or CV Risk in the US
    Published Date: June 27, 2022
    Patient Perceptions of and Preferences Between Characteristics of Injectable Diabetes Treatments.
    Published Date: July 23, 2021

    Can't find what you're looking for? Contact us for answers to your medical questions.

    • Copyright
    • Terms of Use
    • Privacy Statement
    • Consumer Health Privacy Notice
    • Accessibility Statement
    • Sitemap
       

      This site is intended for US Healthcare Professionals only.

      4.0.66 5/2025 | GLOOTH00001 04/2015 | © Lilly USA, LLC 2025. All rights reserved.

      Product names listed above are trademarks or registered trademarks owned by or licensed to Eli Lilly and Company, its subsidiaries, or affiliates

      California Consumer Privacy Act (CCPA) Opt-Out Icon Your Privacy Choices
      Cookie Settings
      Facebook X LinkedIn
      Lilly